Skip to main content

Table 4 Univariate and multivariate analysis of parameters associated with the risk of ncRILD

From: Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child–Pugh grade B patients with locally advanced hepatocellular carcinoma

Variable

Univariate analysis

Multivariate analysis

OR

95%CI

p value

OR

95%CI

p value

Sex, male versus female

1.51

0.16–13.88

0.716

   

Age (years)

1.02

0.96–1.08

0.558

   

Bodyweight (kg)

1.03

0.98–1.08

0.216

   

Radiographic liver cirrhosis

0.83

0.28–2.45

0.735

   

Hepatitis etiology

      

Hepatitis B virus

1.03

0.19–5.49

0.973

   

Hepatitis C virus

0

0.00-Inf

0.991

   

Other

1.41

0.25–8.03

0.696

   

ECOG PS

      

0

Reference

–

–

   

1

1.06

0.30–3.78

0.931

   

2

0

0.00-Inf

0.992

   

Total bilirubin (μmol/L), > 21 versus ≤ 21

1.38

0.47–4.09

0.556

   

Albumin (g/L), ≥ 35 versus < 35

4,751,306

0.00-Inf

0.991

   

PT (sec), > 13 versus ≦ 13

4.60

1.34–15.85

0.016

4.15

1.11–15.53

0.035

Child–Pugh score

      

7

Reference

–

–

   

8

0.58

0.12–2.96

0.516

   

9

1.61

0.14–19.08

0.707

   

ALBI score

1.16

0.25–5.38

0.849

   

ALBI Grade, 2 versus 3

1.78

0.52–6.11

0.359

   

AST (U/L), > 40 versus ≤ 40

1.00

0.30–3.26

0.994

   

ALT (U/L), > 40 versus ≤ 40

0.91

0.31–2.70

0.871

   

ALP (U/L), > 150 versus ≤ 150

2.95

0.92–9.47

0.068

   

WBC (10^12/L), ≥ 4 versus < 4

1.48

0.4–5.48

0.56

   

HGB (g /L), ≥ 110 versus < 110

1.69

0.55–5.17

0.359

   

PLT (10^9/L), ≥ 100 versus < 100

1.17

0.28–4.90

0.833

   

ANC (10^9/L), ≥ 2 versus < 2

2.89

0.58–14.45

0.195

   

ALC (10^9/L), ≥ 0.8 versus < 0.8

0.68

0.2–2.39

0.551

   

Alpha fetoprotein (ng/ml), < 400 versus ≥ 400

1.21

0.41–3.56

0.735

   

Max tumor size (cm)

1.02

0.92–1.14

0.686

   

Tumor number, ≥ 3 versus < 3

5.68

1.19–27.15

0.029

5.84

1.12–30.29

0.036

Macrovascular invasion, yes versus no

2.27

0.58–8.88

0.237

   

Extrahepatic metastasis, yes versus no

1.89

0.63–5.65

0.257

   

BCLC stage

      

A

Reference

–

–

   

B

42,544,812

0.00-Inf

0.991

   

C

13,347,392

0.00-Inf

0.992

   

Dose per fraction, Gy, ≥ 2.7 versus < 2.7

1.95

0.61–6.25

0.261

   

GTV (cc/ml), ≥ 257.9 versus < 257.9

1.58

0.49–5.07

0.445

   

EQD28 (Gy), ≥ 54.3 versus < 54.3

1.29

0.42–3.98

0.653

   

NLV (cc/ml), ≥ 565.2 versus < 565.2

4,837,693

0.00-Inf

0.991

   

Dmean (Gy), ≥ 15.1 versus < 15.1

4.00

1.16–13.74

0.028

4.31

1.14–16.28

0.031

Prior treatment

      

TACE

1.13

0.32–4.02

0.846

   

RFA

0.66

0.07–6.09

0.716

   

Surgical resection

0.50

0.15–1.74

0.278

   

Systemic therapy

0.97

0.27–3.45

0.959

   
  1. ALBI, albumin–bilirubin; ALC, absolute lymphocyte count; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; Dmean, mean dose to the normal liver; ECOG PS, Eastern Cooperative Oncology Group-performance status; EQD2, equivalent dose in 2‑Gy fractions; GTV, gross tumor volume; HGB, hemoglobin; NLV, normal liver volume; OR, odds ratio; PLT, platelets; PT, prothrombin time; RFA, radiofrequency ablation; RT, radiotherapy; TACE, transcatheter chemoembolization; WBC, white blood cells; 8, using LQ model, α/β = 8 Gy
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us